VF
VVOS icon

Virtu Financial’s Vivos Therapeutics VVOS Stock Holding History

Virtu Financial’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,034
Closed -$26K – 1950
2023
Q2 		$26K Buy
2,034
+193
+10% +$1.89K ﹤0.01% 1223
2023
Q1 		$16K Buy
+1,841
New +$40.3K ﹤0.01% 1291
2022
Q3 		– Sell
-472
Closed -$15K – 2277
2022
Q2 		$15K Buy
+472
New +$19.6K ﹤0.01% 1379
2021
Q4 		– Sell
-1,413
Closed -$143K – 2215
2021
Q3 		$143K Buy
+1,413
New +$149K 0.01% 1024

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial's VVOS Position: Q3 2023 in Review

Virtu Financial sold out of Vivos Therapeutics (VVOS) in Q3 2023, closing a stake of 2,034 shares — an estimated $26K sold.

Virtu Financial first reported a position in VVOS in Q3 2021 and held it in 4 quarters. The position peaked at $143K in Q3 2021. 28 funds tracked by Wall St. Rank hold VVOS as of Q3 2023.

  • Virtu Financial reported no remaining Vivos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 2,034 Vivos Therapeutics shares in Q3 2023, an estimated $26K.
  • Virtu Financial first reported a position in Vivos Therapeutics in Q3 2021 and held it in 4 quarters.
  • Virtu Financial's Vivos Therapeutics position peaked at $143K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.